Top Page
TNL Mediagene
(NASDAQ:TNMG)
TNL Mediagene (TNMG) vs. SPDR S&P 500 ETF (SPY)
TNL Mediagene Business Overview & Revenue Model
TNL Mediagene Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 60.57M | 48.49M | 35.84M | 20.01M |
| Gross Profit | 16.54M | 17.74M | 12.65M | 7.74M |
| EBITDA | -73.81M | -73.92M | 1.33M | -10.01M |
| Net Income | -83.41M | -85.00M | -804.98K | -11.01M |
Balance Sheet | ||||
| Total Assets | 86.05M | 92.92M | 119.62M | 26.53M |
| Cash, Cash Equivalents and Short-Term Investments | 1.90M | 3.65M | 3.03M | 3.91M |
| Total Debt | 20.24M | 23.14M | 17.59M | 6.71M |
| Total Liabilities | 51.19M | 56.51M | 47.25M | 50.67M |
| Stockholders Equity | 34.86M | 36.40M | 72.62M | -25.30M |
Cash Flow | ||||
| Free Cash Flow | -11.21M | -10.30M | -1.68M | -1.04M |
| Operating Cash Flow | -11.13M | -10.21M | -1.42M | -760.11K |
| Investing Cash Flow | 475.34K | 947.95K | 252.74K | -2.36M |
| Financing Cash Flow | 9.21M | 10.00M | 530.97K | 4.99M |
TNL Mediagene Technical Analysis
TNL Mediagene Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $16.47M | -32.61 | ― | ― | ― | ― | |
44 Neutral | $3.84M | -1.26 | -50.26% | ― | -66.59% | 67.63% | |
41 Neutral | $9.33M | -0.05 | -164.27% | ― | 4.59% | -920.22% | |
38 Underperform | $2.96M | -0.03 | ― | ― | -62.46% | -12.90% | |
31 Underperform | $4.87M | -1.23 | -194.72% | ― | -11.51% | 74.52% |
TNL Mediagene Corporate Events
On January 20, 2026, TNL Mediagene received confirmation from Nasdaq that it had regained compliance with the exchange’s minimum bid price requirement, after the company’s ordinary shares closed at or above $1.00 for 15 consecutive trading days between December 23, 2025, and January 14, 2026. While this removes the immediate risk to its Nasdaq Capital Market listing following a December 19, 2025 panel decision, Nasdaq has placed the company under a one-year Discretionary Panel Monitor, under which any future breach of continued listing standards during the monitoring period would trigger an automatic delisting determination without the usual cure or compliance grace periods, raising the stakes for management and shareholders as the group works to maintain long-term compliance.
The most recent analyst rating on (TNMG) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on TNL Mediagene stock, see the TNMG Stock Forecast page.
On December 23, 2025, TNL Mediagene was informed by a Nasdaq Hearings Panel that its request for continued listing on the Nasdaq Capital Market had been granted, provided it regains compliance with Nasdaq’s $1 bid price requirement (Listing Rule 5550(a)(2)) by January 7, 2026 and promptly reports any material events that could affect that compliance. The conditional reprieve follows a November 6, 2025 staff determination to delist the stock for failure to meet the $1 bid price threshold after a 180-day grace period, TNL Mediagene’s appeal and hearing request on November 13, 2025, and a December 16, 2025 panel hearing at which the company presented its remediation plan, including a reverse share split announced on December 19; the shares will remain traded on Nasdaq pending the panel’s final written decision after the January 7 deadline, underscoring a critical near-term milestone for investors and the company’s U.S. listing status.
The most recent analyst rating on (TNMG) stock is a Sell with a $0.13 price target. To see the full list of analyst forecasts on TNL Mediagene stock, see the TNMG Stock Forecast page.
On December 19, 2025, TNL Mediagene announced it will implement a 1-for-20 share consolidation of its ordinary shares, following shareholder approval on December 2, 2025 and board approval of the final ratio on December 9, 2025. The reverse split, which is expected to take effect for trading on a split-adjusted basis on the Nasdaq Capital Market on December 23, 2025 under the same ticker “TNMG” with a new CUSIP, will reduce the number of outstanding ordinary shares from 51,115,851 to approximately 2,555,793, with fractional shares rounded up and all shareholders’ percentage ownership largely preserved. The move is aimed at lifting the company’s per-share trading price to restore compliance with Nasdaq’s $1.00 minimum bid requirement and to broaden its appeal among institutional investors, while triggering proportional adjustments to the exercise or conversion terms of outstanding warrants, earnout shares, equity awards, and other equity instruments, signaling an effort to stabilize its listing status and strengthen its capital markets profile.
The most recent analyst rating on (TNMG) stock is a Sell with a $0.27 price target. To see the full list of analyst forecasts on TNL Mediagene stock, see the TNMG Stock Forecast page.
On December 8, 2025, TNL Mediagene amended its securities purchase agreement with 3i, LP, issuing a second tranche convertible note valued at $1,666,667. This amendment introduces revised terms for future note issuances, including an 18-month maturity, no installment payments for the first six months, and a cap on acceleration linked to trading volume. Additionally, TNL Mediagene issued a five-year warrant to purchase ordinary shares, exercisable under specific conditions, further solidifying its financial strategy and potentially impacting its market positioning and investor relations.
The most recent analyst rating on (TNMG) stock is a Sell with a $0.27 price target. To see the full list of analyst forecasts on TNL Mediagene stock, see the TNMG Stock Forecast page.
On December 5, 2025, TNL Mediagene announced the results of its Annual General Meeting of Shareholders held on December 2, 2025. The meeting, initially convened on November 25, 2025, saw all proposals approved, including an increase in authorized share capital, amendments to the company’s memorandum and articles of association, and the election of new directors. These changes are expected to impact the company’s governance and operational strategies, potentially influencing its market positioning and stakeholder interests.
The most recent analyst rating on (TNMG) stock is a Sell with a $0.27 price target. To see the full list of analyst forecasts on TNL Mediagene stock, see the TNMG Stock Forecast page.
TNL Mediagene, a company operating in the media industry, announced a change in its certifying accountant. On October 9, 2025, PricewaterhouseCoopers, Taiwan, declined to stand for re-election as the independent registered public accounting firm for the company. Subsequently, on November 20, 2025, TNL Mediagene appointed Marcum Asia CPAs LLP as its new independent registered public accounting firm. This change follows a careful evaluation process and was approved by the audit committee of the board of directors. The transition is significant as it addresses material weaknesses in the company’s internal controls over financial reporting, which were noted in previous fiscal years.
The most recent analyst rating on (TNMG) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on TNL Mediagene stock, see the TNMG Stock Forecast page.
TNL Mediagene announced its upcoming Annual General Meeting of Shareholders, scheduled for November 25, 2025, where key proposals will be voted on, including a significant increase in authorized share capital from $50,000 to $500,000. This increase aims to provide flexibility for future capital raising and corporate purposes, supporting the company’s M&A roll-up strategy and digital asset treasury initiatives. The adoption of an Amended and Restated Memorandum and Articles of Association is also proposed to modernize the company’s constitutional documents, reflecting current laws and market practices.
The most recent analyst rating on (TNMG) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on TNL Mediagene stock, see the TNMG Stock Forecast page.